{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:23:15Z","timestamp":1789402995263,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vhri.2022.10.007","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T16:01:20Z","timestamp":1669910480000},"page":"31-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab"],"prefix":"10.1016","volume":"34","author":[{"given":"Ricardo Mesquita","family":"Camelo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Michel","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiara Silva","family":"Ara\u00fajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Roberto L\u00facio","family":"Muniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Augusto Afonso","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Godman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suely Meireles","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco de Assis","family":"Acurcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony P.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Alvares-Teodoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vhri.2022.10.007_bib1","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.hoc.2021.07.006","article-title":"Hemophilia A (factor VIII deficiency)","volume":"35","author":"Seaman","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.vhri.2022.10.007_bib2","doi-asserted-by":"crossref","unstructured":"Srivastava A, Santagostino E, Dougall A, et\u00a0al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.","DOI":"10.1111\/hae.14046"},{"issue":"11","key":"10.1016\/j.vhri.2022.10.007_bib3","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/17474086.2018.1521718","article-title":"The importance of inhibitor eradication in clinically complicated hemophilia A patients","volume":"11","author":"Oldenburg","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.vhri.2022.10.007_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ejh.13193","article-title":"Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients","volume":"102","author":"Ljung","year":"2019","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.007_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.15728","article-title":"on the behalf of the HEMFIL Study Group. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study","volume":"186","author":"Jardim","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.007_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1055\/s-0032-1309286","article-title":"FEIBA: a prohemostatic agent","volume":"38","author":"Cromwell","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"1 suppl 1","key":"10.1016\/j.vhri.2022.10.007_bib7","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1053\/j.seminhematol.2005.11.025","article-title":"Mechanism of action of recombinant activated factor VII: an update","volume":"43","author":"Hedner","year":"2006","journal-title":"Semin Hematol"},{"issue":"15","key":"10.1016\/j.vhri.2022.10.007_bib8","first-page":"1697","article-title":"Emicizumab: a review in haemophilia","volume":"79","author":"Blair","year":"2019","journal-title":"A.\u00a0Drugs"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.007_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1160\/TH15-07-0568","article-title":"Spanish consensus guidelines on prophylaxis with bypassing agents in patients with haemophilia and inhibitors","volume":"115","author":"L\u00f3pez-Fern\u00e1ndez","year":"2016","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.007_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057018","article-title":"AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors","volume":"12","author":"Matsushita","year":"2022","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.007_bib11","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/hae.13819","article-title":"Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis","volume":"25","author":"Batsuli","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.vhri.2022.10.007_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211032452","article-title":"Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)","volume":"12","author":"Escuriola Ettingshausen","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"12","key":"10.1016\/j.vhri.2022.10.007_bib13","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1160\/TH17-05-0365","article-title":"Use of bypassing agents and risk of thromboembolic events in patients with haemophilia and inhibitors","volume":"117","author":"Bykov","year":"2017","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.vhri.2022.10.007_bib14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/14740338.2019.1551356","article-title":"Evaluating the safety of emicizumab in patients with hemophilia A","volume":"17","author":"Langer","year":"2018","journal-title":"Expert Opin Drug Saf"},{"issue":"8","key":"10.1016\/j.vhri.2022.10.007_bib15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/jth.14556","article-title":"Emicizumab and thrombosis: the story so far","volume":"17","author":"Makris","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.vhri.2022.10.007_bib16","first-page":"175","article-title":"Hemophilia A in Brazil - epidemiology and treatment developments","volume":"5","author":"Ferreira","year":"2014","journal-title":"J\u00a0Blood Med"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2022.10.007_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/bloodadvances.2019GS121559","article-title":"Building the National Program of Inherited Bleeding Disorders in Brazil","volume":"3","author":"Rezende","year":"2019","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.vhri.2022.10.007_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0256265","article-title":"Predictors of the outcome of immune tolerance induction in patients with haemophilia A and inhibitors: the Brazilian Immune Tolerance (BrazIT) study protocol","volume":"16","author":"Camelo","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.vhri.2022.10.007_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/ejh.13108","article-title":"The socioeconomic burden of patients affected by hemophilia with inhibitors","volume":"101","author":"D\u2019Angiolella","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.007_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10198-021-01339-4","article-title":"Costs and management of patients with hemophilia A in France: the Hemraude study","volume":"23","author":"Laurendeau","year":"2022","journal-title":"Eur J Health Econ"},{"issue":"2","key":"10.1016\/j.vhri.2022.10.007_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1055\/s-0039-3401822","article-title":"Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors","volume":"120","author":"Cortesi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"suppl 5","key":"10.1016\/j.vhri.2022.10.007_bib22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/hae.14082","article-title":"The societal burden of haemophilia A. III \u2013 the potential impact of emicizumab on costs of haemophilia A in Australia","volume":"26","author":"Brown","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.007_bib23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/hae.14129","article-title":"Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France","volume":"27","author":"Polack","year":"2021","journal-title":"Haemophilia"},{"issue":"2","key":"10.1016\/j.vhri.2022.10.007_bib25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/17474086.2021.1875817","article-title":"Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors","volume":"14","author":"Carcao","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.vhri.2022.10.007_bib26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2147\/TCRM.S205310","article-title":"Concomitant use of rFVIIa and emicizumab in people with hemophilia a with inhibitors: current perspectives and emerging clinical evidence","volume":"16","author":"Linari","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"10.1016\/j.vhri.2022.10.007_bib28","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/jth.15878","article-title":"Time between inhibitor detection and start of immune tolerance induction: association with outcome in the BrazIT Study","volume":"20","author":"Camelo","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"8","key":"10.1016\/j.vhri.2022.10.007_bib29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/17474086.2021.1957826","article-title":"Overcoming the challenges of treating hemophilia in resource-limited nations: a focus on medication access and adherence","volume":"14","author":"Ghosh","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.007_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2516.2005.01085.x","article-title":"Knocking down the price of factor concentrates in Brazil","volume":"11","author":"Rezende","year":"2005","journal-title":"Haemophilia"},{"key":"10.1016\/j.vhri.2022.10.007_bib31","series-title":"StatPearls. Treasure Island","article-title":"Managed care economics","author":"Namburi","year":"2022"},{"issue":"24","key":"10.1016\/j.vhri.2022.10.007_bib33","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.vhri.2022.10.007_bib34","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/blood-2006-04-017988","article-title":"A\u00a0randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study","volume":"109","author":"Astermark","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.vhri.2022.10.007_bib35","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/hae.12750","article-title":"A\u00a0systematic review of definitions and reporting of bleeding outcome measures in haemophilia","volume":"21","author":"Chai-Adisaksopha","year":"2015","journal-title":"Haemophilia"},{"issue":"9","key":"10.1016\/j.vhri.2022.10.007_bib36","first-page":"CD011441","article-title":"Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors","volume":"9","author":"Chai-Adisaksopha","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.vhri.2022.10.007_bib37","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1111\/hae.12456","article-title":"Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy","volume":"20","author":"Abbonizio","year":"2014","journal-title":"Haemophilia"},{"issue":"16","key":"10.1016\/j.vhri.2022.10.007_bib38","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.vhri.2022.10.007_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28942","article-title":"Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab","volume":"68","author":"Garcia","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.vhri.2022.10.007_bib40","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1111\/hae.14432","article-title":"Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.vhri.2022.10.007_bib41","doi-asserted-by":"crossref","unstructured":"Kruse-Jarres R, Peyvandi F, Oldenburg J, et\u00a0al. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies [published online ahead of print August 8, 2022]. Blood Adv. doi:10.1182\/bloodadvances.2022007458.","DOI":"10.1182\/bloodadvances.2022007458"},{"issue":"1","key":"10.1016\/j.vhri.2022.10.007_bib42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/hae.14212","article-title":"Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: real-world experience from a large comprehensive treatment centre in the US","volume":"27","author":"Lewandowska","year":"2021","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.vhri.2022.10.007_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-059667","article-title":"AOZORA: long-term safety and joint health in paediatric persons with haemophilia A without factor VIII inhibitors receiving emicizumab \u2013 protocol for a multicentre, open-label, phase IV clinical study","volume":"12","author":"Shima","year":"2022","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.vhri.2022.10.007_bib44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.13762","article-title":"The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab","volume":"25","author":"Carcao","year":"2019","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.007_bib45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/hae.12621","article-title":"Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment","volume":"21","author":"Earnshaw","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.vhri.2022.10.007_bib46","series-title":"Secondary Analysis of Electronic Health Records","first-page":"351","article-title":"Markov models and cost effectiveness analysis: applications in medical research","author":"Komorowski","year":"2016"},{"issue":"3","key":"10.1016\/j.vhri.2022.10.007_bib47","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/hae.14292","article-title":"Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study","volume":"27","author":"Yu","year":"2021","journal-title":"Haemophilia"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109922001947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:14:19Z","timestamp":1761941659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109922001947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":44,"alternative-id":["S2212109922001947"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2022.10.007","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2022.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}